Current Law Journal Content
Washington & Lee Law School
  Current Law Journal Content
                  an index to legal periodicals
 


  Bio-Science Law Review   (United Kingdom)
  Volume 7, Issue 2, 2004/2005
  homepage                   other issues
 

  • ARTICLES
  • Disclaimers Get Green Light
        Hsu Min Chung
        p.77                                                                                        +cite        
        The Enlarged Board of Appeal has recently clarified the European Patent office's position on disclaimers following two conflicting decisions from their Technical Boards of Appeal. The Enlarged Board of Appeal's decision has helped to lift the uncertainty surrounding the use of disclaimers and the validity of patent claims in which they have been used. This article outlines the reason behind the Enlarged Board of Appeal's Decision and provides examples of circumstances in which disclaimers can be used.
  • Erythropoietin in the UK courts: A set Back for Gene Patents?
        Stephen Crespi
        p.81                                                                                        +cite        
        The Progress through the English courts of the KIRIN-AMGEN UK patent on the blockbuster drug Erythropoietin is reviewed here from the viewpoint of a patent attorney. After the House of Lords held invalid its important product claims to the recombinant protein, these were removed by amendment allowing the process claims to survive for the short time before the natural expiry date of the patent. This contribution focuses on the product-by-process claims and their interpretation and reflects on the apparent demise of long established UK practice in this regard.
  • Narrow Trousers and Narrow Patents, A Health Risk? Product Protection of Purpose Bound Protection for Biotechnological Inventions
        S J R Bostyn
        p.89                                                                                        +cite        
        Potential broad protection for DNA patent causes concerns. One of the remedies applied by some countries is to limit protection from absolute product protection to purpose-bound protection. Whether such a solution is a correct interpretation of the biotech directive, as is claimed, can be seriously doubted. Similarly, it can be seriously doubted whether such a limitation provides any solution to the alleged problem of blocking patents and patent thickets.

  • NEWS
  • AUSTRALIA - Biotechnology company reporting - CANADA - Data Protection - NEW ZEALAND - Patents - Draft Patents Bill - UNITED KINGDOM - - Patents - Licensing Agreements - royalties clause CAT v Abbott - Patents - Apotex not infringing GlaxoSmithKline Paroetine Patent - Insurance - genetic testing moratorium extended - Taxation - Tax Boost for Research 'spin-out' companies - UNITED STATES - Patents - claims construction -in re Crish - EUROPEAN COURT OF JUSTICE - Medicinal Products - meaning of Essentially similar - SmithKline Beecham v Laegemiddelstyrelsen -Parallel Imports - Pharmaceuticals - Syfait v GlaxoSmithKline - EUROPEAN PATENT OFFICE - Patents - The Myriad//Breast Cancer Patents - An update
        p.96                                                                                        +cite